– UK, London – NetScientific plc (LON: NSCI), the life sciences, technology, investment and commercialisation Group, today announced that John Clarkson is stepping to Executive Chairman and that Clive Sparrow joined its Board as a Non-Executive Director, effective immediately.
John will also be appointed as Board Chairman of ProAxsis, and as a Board Director of Glycotest (NetScientific subsidiaries), while Clive will Chair the Audit Committee of NetScientific plc.
The company also confirmed the appointment of Stephen Crowe to full-time CFO. Stephen is a highly experienced finance professional who has previously provided financial consultancy services to NetScientific.
Dr Ilian Iliev, CEO said: “I am delighted to announce this further significant step in our planned strategy implementation. John Clarkson’s move to an Executive Chairman position will let NetScientific further benefit from his wealth of commercial, international and corporate governance expertise, as we continue to build out our cross-Atlantic strategy and drive shareholder value. We welcome Clive to the Board of NetScientific, and look forward to his contributions as Chair of the Audit Committee and more broadly. We also welcome Professor Stephen Smith’s support in building out the Scientific and Industry Advisory Group and contributing his networks and industry standing. I expect that the strengthened, experienced and balanced Board will strengthen the Executive’s ability to implement the Group’s strategy and grow shareholder value.”
About John Clarkson
John joined the NetScientific Board in December 2019, then was appointed as Non-executive Chairman in March 2020, and since then has been working alongside the CEO in the strategy review and implementation, including leading the acquisition of EMV Capital and the £2.3 million placing in August 2020. John will continue to work alongside and support the CEO with a focus on the implementation of the company’s turnaround and growth strategy, Board representation and proactive management of the portfolio companies and leading work on special projects. He will also contribute his corporate experience working in North America to accelerate NetScientific’s cross-Atlantic strategy. John joins the ProAxsis Limited Board as Chairman and the Glycotest Board as a Director.
About Clive Sparrow
Clive is an experienced Director and Chairman of an Audit Committee, with a background at the NHS, PWC and HM Treasury. He is also a Non-Executive Director serving on the board of the largest community healthcare NHS Trust in London. He has a proven track record in strategy development, transformational change, risk management and performance improvement. His sector specialities are the government, the NHS, and regulation.
Clive had a successful career as a management consultant with two professional services firms: Grant Thornton and PricewaterhouseCoopers. For three years, he worked as a Director in HM Treasury, driving the delivery of a successful change programme. He has also set up and led two profitable start-up companies.
Clive is a Fellow of the Association of Chartered Certified Accountants, a Chartered Public Finance Accountant and a member of the Healthcare Financial Management Association. He holds a degree in Economics from the University of Nottingham.
About ProAxsis
ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has developed activity-based immunoassays for the specific quantification of the active form of Neutrophil Elastase, Proteinase 3 and Cathepsin G.
In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.
Aside from the provision of assays, ProAxsis can offer a sample analysis service at its purpose-built laboratory facility in Belfast and is currently supporting several pharmaceutical company-sponsored Phase I, II and III clinical trials.
ProAxsis is a fully owned subsidiary of NetScientific Plc.
For more information: https://proaxsis.com/
About Glycotest Inc.
Glycotest Inc. is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients with serious liver disease, and a subsidiary of NetScientific. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. In October 2018 the company signed a $10mln Series A milestone-based investment round with global pharma corporation Fosun Pharma.
Glycotest is a 65.6% subsidiary of NetScientific Plc.
For more information: https://www.glycotest.com/
About NetScientific
NetScientific is a life sciences, technology, investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value.
For more information: https://netscientific.net/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
